Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: Neuropharmacology. 2014 Jul 15;86:161–173. doi: 10.1016/j.neuropharm.2014.07.006

Figure 2. Exposure to WIN in early adolescence suppresses oscillations in vitro in adult mPFC, but not SCx, via CB1Rs.

Figure 2

(A) Experimental time course. Animals were injected with the CB1R/CB2R agonist WIN (2 mg/kg) or vehicle + the CB1R antagonist AM251 (2 mg/kg) in early adolescence (P35–P40) once daily for six days. LFPs were recorded in vitro in slices of adult mPFC (B–D) or SCx (E,F). (B,C) Cumulative probability distributions of normalized oscillation power plotted on a log scale from LFPs recorded in mPFC of adult mice treated with vehicle (solid line) or (B) WIN (dashed line) or (C) AM251 (dashed line) from P35–P40. Kolmogorov-Smirnoff tests were used to compare the effect of cannabinoid treatment on normalized oscillation power. (D) Plots as in (B,C), except normalized power was compared between animals treated with WIN or AM251 + WIN, and between vehicle and AM251 + WIN with KS tests. (E,F) Plots as in (B,C) for LFPs recorded in SCx.